This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, eHealth) (354) MRC funded proposals with peer-review reports (UK) (2)

Published on in Vol 6, No 9 (2017): September

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Authors of this article:

Keira Annie Markey1, 2 Author Orcid Image ;   Ryan Ottridge3 Author Orcid Image ;   James L Mitchell1, 2 Author Orcid Image ;   Caroline Rick3 Author Orcid Image ;   Rebecca Woolley3 Author Orcid Image ;   Natalie Ives3 Author Orcid Image ;   Peter Nightingale4 Author Orcid Image ;   Alexandra J Sinclair1, 2 Author Orcid Image
Article Authors Cited by (35) Tweetations (10) Metrics

Keira Annie Markey   1, 2 , MRCP ;   Ryan Ottridge   3 , MPhil ;   James L Mitchell   1, 2 , MRCP ;   Caroline Rick   3 , PhD ;   Rebecca Woolley   3 , MSc ;   Natalie Ives   3 , MSc ;   Peter Nightingale   4 , PhD ;   Alexandra J Sinclair   1, 2 , PhD

1 Neurometabolism, Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

2 Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, United Kingdom

3 Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

4 Institute of Translational Medicine, Queen Elizabeth Hospital, Birmingham, United Kingdom

Corresponding Author:

  • Alexandra J Sinclair, PhD
  • Neurometabolism, Institute of Metabolism and Systems Research
  • College of Medical and Dental Sciences
  • University of Birmingham
  • The Medical School
  • Edgbaston
  • Birmingham, B15 2TT
  • United Kingdom
  • Phone: 44 1214158708
  • Email: a.b.sinclair@bham.ac.uk